Bio-Connect
IHC-P analysis of human lung carcinoma using GTX81601 Interferon gamma Receptor 2 antibody, C-term.
IHC-P analysis of human lung carcinoma using GTX81601 Interferon gamma Receptor 2 antibody, C-term.
IHC-P analysis of human lung carcinoma using GTX81601 Interferon gamma Receptor 2 antibody, C-term.

Interferon gamma Receptor 2 antibody, C-term

GTX81601
GeneTex
TargetIFNGR2
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    Interferon gamma Receptor 2 antibody, C-term
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1:1000. IHC-P: 1:50-1:100. FACS: 1:10-1:50. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Formulation
    Liquid
  • Gene ID3460
  • Target name
    IFNGR2
  • Target description
    interferon gamma receptor 2
  • Target synonyms
    AF-1; IFGR2; IFN-gamma receptor 2; IFN-gamma-R2; IFN-gamma-R-beta; IFNGT1; IMD28; interferon gamma receptor 2; interferon gamma receptor accessory factor-1; interferon gamma receptor beta chain; interferon gamma transducer 1
  • Protein IDP38484
  • Protein Name
    Interferon gamma receptor 2
  • Scientific Description
    This gene (IFNGR2) encodes the non-ligand-binding beta chain of the gamma interferon receptor. Human interferon-gamma receptor is a heterodimer of IFNGR1 and IFNGR2. Defects in IFNGR2 are a cause of mendelian susceptibility to mycobacterial disease (MSMD), also known as familial disseminated atypical mycobacterial infection. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance. [provided by RefSeq, Jul 2008]
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • MLLT6 maintains PD-L1 expression and mediates tumor immune resistance. Sreevalsan S et al., 2020 Dec 3, EMBO Rep
    Read more
  • miR-4666-3p and miR-329 Synergistically Suppress the Stemness of Colorectal Cancer Cells via Targeting TGF-beta/Smad Pathway. Ye J et al., 2019, Front Oncol
    Read more